Resveratrol in Postmenopausal Women With High Body Mass Index

Completed · Phase 1

Conditions studied: Healthy, no Evidence of Disease

In brief

This pilot phase I trial studies resveratrol in postmenopausal women with high body mass index. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of resveratrol may keep cancer from forming. Studying samples of blood and urine in the laboratory from postmenopausal women who are taking resveratrol may help doctors learn more about the effects of resveratrol on biomarkers.

Key facts

Study ID

NCT01370889

Run by

National Cancer Institute (NCI)

People needed

46

Starts

2011-06-01

Expected to finish

2012-07-01

Last updated by the study team

2014-10-09

Who can join

Age: 35 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy postmenopausal women with a body mass index (BMI) of 25 kg/m\^2 or greater
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 70% or above
• Leukocytes >= 3,000/uL
• Absolute neutrophil count (ANC) >= 1,500/uL
• Platelets >= 100,000/uL
• Total bilirubin =< 2.0 mg/dL
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 times upper limit of normal (ULN)
• Creatinine =< 1.0 times ULN
• Ability and willingness to limit resveratrol-containing foods to no more than one serving each per day for about 14 weeks
• Negative mammogram or negative workup of mammographic findings within prior 12 months prior to enrollment for women >= 50 years of age
• Ability to understand and the willingness to sign a written informed consent document

You may not qualify if…

• Have had invasive cancer(s) within the past 5 years except non-melanoma skin cancer
• Within 3 months of or concurrent usage of any other investigational agents
• History of allergic reactions attributed to resveratrol
• Unwilling or unable to refrain from taking herbal medicines and dietary supplements
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Within 3 months of or concurrent estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens; vaginal estrogen is acceptable.
• Within 3 months of or concurrent usage of tamoxifen, raloxifene, other selective estrogen-receptor modulators, or aromatase inhibitors
• Regular usage (more than 2 times a week) of estrogenic supplements or herbal remedies (e.g., Remifemin, black cohosh, red clover, dong quai, soy isoflavones, dehydroepiandrosterone [DHEA], flaxseed, diindolylmethane [DIM], genistein, and daidzein) within the past 3 months or concurrently; dietary consumption of phytoestrogens/isoflavones (such as soy, tofu, millet, barley, natto, tempeh, miso, soy milk, soy sauce) is acceptable as these sources are not concentrated
• Concurrent use of anti-diabetic drugs such as:
• Insulin
• Sulfonylureas (e.g., glipizide, glyburide, or glimepiride)
• Meglitinides (e.g., repaglinide or nateglinide)
• Biguanides (e.g., metformin)
• Thiazolidinediones (e.g., rosiglitazone or pioglitazone)
• Alpha-glucosidase inhibitors (e.g., acarbose or miglitol)
• Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin)
• Concurrent use of warfarin or phenytoin

Where it is running

• Arizona Cancer Center - Tucson — Tucson, Arizona, United States
• University of Arizona Health Sciences Center — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.